Towards a Rational Design of an Asymptomatic Clinical Herpes Vaccine: The Old, the New, and the Unknown

Figure 2

Illustration of steps in developing an asymptomatic lipopeptides-base herpes vaccine. The lipopeptide vaccine formulation is developed following multistep strategy. This starts from the identification of a symptomatic and asymptomatic herpes population and highly immunogenic HSV proteins. Next, asymptomatic CD4⁺ and CD8⁺ T-cell epitopes are discovered and covalently linked to a TLR2 agonist (Palmitic acid) leading to self-adjuvanting lipopeptides [12].